October 05, 2026 / By Tim Head / in Retatrutide
Retatrutide is an investigational triple-agonist peptide medicine developed by Eli Lilly. Its clinical development began with early human studies and progressed through Phase 2 and Phase 3 trials. Research has evaluated obesity, diabetes, cardiovascular, and other metabolic outcomes in adults with obesity. Despite encouraging trial findings, retatrutide remains unapproved and continues to undergo clinical and regulatory evaluation.
Retatrutide’s development has progressed through multiple stages, with each phase providing researchers with new clinical data. The timeline below highlights the major milestones, from its earliest human studies to the ongoing Phase 3 research program.
Retatrutide, also known as LY3437943, is a once-weekly investigational medicine that activates three hormone receptors: GIP, GLP-1, and glucagon. Researchers are studying this triple-agonist mechanism, which includes the glucagon receptor, for its potential effects on body weight, blood glucose, and other metabolic outcomes. Because retatrutide remains investigational, it should be distinguished from approved medicines used for similar conditions. Should be distinguished from approved medicines used for similar conditions.
Because retatrutide remains investigational, it should be distinguished from approved medicines used for similar conditions. For readers researching related metabolic and weight-management compounds, Online UK steroid shop provides additional information about products available through its platform.
Retatrutide’s development has progressed through several stages of clinical research, from early human studies to larger Phase 2 and Phase 3 trials. Each stage has helped researchers evaluate its safety, tolerability, weight-related effects, and potential benefits for metabolic conditions. The timeline below highlights the major milestones that have shaped retatrutide’s investigational development.
The clinical development phase of LY3437943 progressed to human trials in 2019. Laboratory studies analyzed the chemical's safety, tolerability, pharmacokinetics, and effects as a receptor agonist.
Subsequent clinical studies involved repeat dosing in obese individuals or those suffering from metabolic disorders, focusing on the effects of higher doses.
After more research on retatrutide and its metabolism, and after repeated dosing, scientists began researching the triple-receptor approach that could be used to develop future peptide-based steroids for weight management.
The triple-receptor mechanism would be important for their research. It is not about studying a single route, but learning about what activating all three receptors can do.
A key milestone was the release of Phase 2 trial results on the steroid's impact in obese or overweight patients in The New England Journal of Medicine in 2023, highlighting significant weight reduction. This study evaluated various weekly dosages of the medication for 48 weeks and found dose-dependent weight loss. Moreover, its safety was assessed as part of the phase 3 clinical trials.
Next, the company introduced the Phase 3 TRIUMPH program.
The first TRIUMPH-1 study started in July 2023, with more than 2,300 obese and overweight participants. There were also cohorts suffering from knee osteoarthritis and obstructive sleep apnea. (Lilly Trials)
Other trials expanded research into people with type 2 diabetes and cardiovascular disease, allowing researchers to examine retatrutide across different patient populations.
Lilly disclosed results from the Phase 3 TRIUMPH-4 study in December 2025, which included participants with obesity and knee osteoarthritis without diabetes.
The study assessed both weight and knee osteoarthritis pain. The results were positive for Lilly, making TRIUMPH-4 the company's first successful retatrutide Phase 3 trial. (Eli Lilly and Company)
Retatrutide advanced in development in 2026. Results from the TRIUMPH-1 trial were good for Lilly in May, and those from TRIUMPH-2 and TRIUMPH-3 (Eli Lilly and Company)
Triumph-2 involved participants with either obesity/overweight and type 2 diabetes, whereas Triumph-3 was about patients who suffered from severe obesity and known heart disease. (Eli Lilly and Company)
The program has now diversified to cover areas such as sleep apnea, cardiovascular and renal endpoints, chronic low back pain, and steatotic liver disease due to metabolic dysfunction. There are several ongoing Phase 3 trials focusing on obesity or overweight. (Lilly)
However, research on other aspects is ongoing. Ongoing phase III trials include studies on weight management, comparative effectiveness, outcomes on diabetes, cardiovascular and renal outcomes, and outcomes on comorbidities in adults with obesity.
For instance, TRIUMPH-6 is investigating whether weight loss can be maintained, while TRIUMPH-Outcomes is investigating cardiovascular and renal outcomes in a significantly larger group of patients. (Lilly Trials)
No. Retatrutide is not currently approved by the FDA. Lilly describes it as an investigational medicine and states that it is currently available only to participants in clinical trials. (Lilly)
Positive clinical-trial results are an important part of steroid development, but regulatory approval requires review of the complete evidence package.
|
Year |
Development Stage |
Key Milestone |
|
2019 |
Early research |
Human clinical testing |
|
2021–2022 |
Early studies |
Expanded clinical investigation |
|
2023 |
Phase 2 |
Important obesity trial results |
|
2023 |
Phase 3 |
TRIUMPH program begins |
|
2025 |
Phase 3 |
First positive Phase 3 results |
|
2026 |
Phase 3 |
Multiple additional results reported |
Human clinical development of LY3437943 was underway by 2019.
Retatrutide has not yet been approved by the FDA, with Eli Lilly set to file its BLA application in the first quarter of 2027.
Most important Phase 3 clinical studies for retatrutide are expected to finish or complete their primary results before the end of 2026.
Retatrutide’s development has progressed from early human research in 2019 to an extensive Phase 3 clinical program targeting metabolic dysfunction-associated steatotic liver disease. Research has examined its effects on obesity, type 2 diabetes, cardiovascular health, sleep apnea, and other metabolic conditions. Although clinical results have generated continued interest, retatrutide for obesity remains an investigational medicine. Ongoing trials and regulatory review will determine its future role in metabolic treatment.
I am a urologist with a focus on kidney transplants and urological surgery. My work involves treating patients with kidney and urinary conditions and providing careful, evidence-based guidance. I also study how anabolic steroids affect the body, especially in bodybuilding, to help people understand their real health impacts and make informed decisions.
